U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07612527) titled 'Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation' on May 21.
Brief Summary: The gastric fundus regulates appetite through orexigenic ghrelin-mediated and anorexigenic visceroceptive pathways. Accordingly, endoscopic gastric fundal mucosal ablation (GFMA) may benefit patients with obesity. Ablation not only affects these mechanisms, but similar to what happens after mucosal ablation for other indications (e.g. ESD for tumor removal), it is expected to cause shrinking of the fundus and reduce gastric volume.
Another potential target to achieve weight loss is gastric emptying. This is a critical step in...